Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab.
Abstract
3047 Background: Immune-related adverse events (irAE) encompass wide-ranging toxicities in patients (pts) taking Ipilimumab. Experienced by many pts on Ipilimumab, they occasionally result in death. As irAE could be indicative of an enhanced immune response to therapy, pts developing these events potentially experience improved therapeutic response and survival. We evaluated the toxicity patterns of irAE in older pts with melanoma receiving Ipilimumab, and the association of irAE with their overall survival (OS). Methods: We identified melanoma pts 65 years or older, treated with Ipilimumab using the Surveillance Epidemiology and End Results (SEER) and Texas Cancer Registry (TCR) linked with Medicare data between 3/2011 and 12/2013. We defined 44 types of irAE based on 228 ICD-9 diagnosis codes; irAE had to occur within 3 months of last treatment and include one or more diagnosis codes, which could not be present within a 6-month window before treatment. We classified pts with irAE as severe if they had a related hospitalization or death within 2 weeks of the claim. We used log rank and multivariable Cox regression to analyze OS. Results: We identified 858 pts with mean age at diagnosis 69.1 years and mean age at treatment 74.8 years. More than half of pts (63.3%) had a Charlson Comorbidity Index of 0. Pts received a median of 3 treatment courses. 510 (60%) pts experienced irAE with 178 pts (20.7%) experiencing severe irAE. The most frequent irAE were colitis (17.5%), hypothyroidism (10.5%), dermatitis (5.4%) and hypophysitis (3.7%). Those with non-severe irAE had improved OS compared with no irAE or severe irAE with median survival years being 1.1, 0.9, and 0.6, respectively (p < 0.001). In the multivariable analysis, severe irAE pts were 28% more likely to die compared to pts with no irAE (p = 0.04). Conclusions: In this retrospective study our findings suggest that the incidence of irAE occurs in elderly melanoma pts at comparable rates to all melanoma pts treated with Ipilimumab. Hypothyroidism occurred more frequently than what has been reported in clinical trials. Pts with non-severe irAE had improved OS compared to pts with no irAE. Pts with severe irAE appeared to have the highest risk of death.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients treated with anti-CTLA-4 antibodies, the association between IRAEs and ICI efficacy has been less uniform.
“In patients treated with anti-CTLA-4 antibodies, this association has been less uniform [21–25].”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [24]
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750 · see citing works
on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0579-z · Cited by 140 · see citing works
Doherty, G. J., Duckworth, A., Davies, S. E., Mells, G. F., Brais, R. J., Harden, S., Parkinson, C., & Corrie, P. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000268 · Cited by 123 · see citing works
Does patient age influence anti-cancer immunity?
Pawelec, G. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0697-6 · Cited by 96 · see citing works
Abdelrahim, M., Mamlouk, O., Lin, H. Y., Lin, J. S., Page, V. D., Abdel‐Wahab, N., Swan, J. T., Selamet, U., Yee, C., Diab, A. K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1927313 · Cited by 51 · see citing works
“Patients in that study who developed nonsevere irAEs had improved OS compared to those with severe irAEs; the latter were 28% more likely to die than patients with no irAEs.(33) However, there was no mention of renal-associated irAEs; therefore, renal function may be unique as far as age and ICI exposure and needs to…”
BackgroundSelf-citationWu, C., Yang, C., Peng, M., Huang, P., Chang, C., Yeh, K., Chen, C., Wang, C., Hsu, C., Chen, I., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07508-7 · Cited by 42 · see citing works
“[27], although ipilimumab rather than anti-PD-1 was used in this study.”
MethodArchibald, W. J., Victor, A. I., Strawderman, M. S., & Maggiore, R. J. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.07.005 · Cited by 36 · see citing works
Melanoma Immunotherapy in the Elderly
Orloff, M. M. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0656-3 · Cited by 31 · see citing works
Siddiqui, B. A., Gheeya, J., Goswamy, R. V., Bathala, T. K., Surasi, D. S., Gao, J., Shah, A. Y., Campbell, M. T., Msaouel, P., Goswami, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002850 · Cited by 24 · see citing works
Leroy, V., Gerard, É., Dutriaux, C., Prey, S., Gey, A., Mertens, C., Beylot-Barry, M., & Pham‐Ledard, A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02298-9 · Cited by 22 · see citing works
Immunotherapy for older patients with melanoma: From darkness to light?
Iacono, D., Vitale, M. G., Basile, D., Pelizzari, G., Cinausero, M., Poletto, E., Pascoletti, G., & Minisini, A. M. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12917 · Cited by 20 · see citing works
“…from MD Anderson and the MSKCC reported the efficacy and safety of the combination regimen on 106 patients older than 80 (Friedman et al., 2016; Mian et al., 2016); the median age of patients receiving ipilimumab plus nivolumab, ipilimumab alone, and nivolumab alone was 82 (range 80–87), 84…”
BackgroundCuring Stage IV Melanoma: Where Have We Been and Where Are We?
Chan, P. Y., & Corrie, P. G. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438654 · Cited by 19 · see citing works
Treatment of Metastatic Melanoma in the Elderly
Seedor, R. S., & Orloff, M. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01257-5 · Cited by 19 · see citing works
Stoff, R., Grynberg, S., Asher, N., Laks, S., Steinberg‐Silman, Y., Schachter, J., Shapira‐Frommer, R., & Ben‐Betzalel, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020058 · Cited by 17 · see citing works
Xu, H., Xu, X., Ge, W., Lei, J.-J., & Cao, D. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920980546 · Cited by 17 · see citing works
Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System
Chen, C., Zhang, C., Wu, B., & Xu, T. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.009 · Cited by 13 · see citing works
Barailler, H., Salomon, G., Dutriaux, C., Prey, S., Gerard, É., Dousset, L., Mertens, C., Beylot-Barry, M., Meyer, N., & Pham‐Ledard, A. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.03.003 · Cited by 7 · see citing works
Anstadt, E. J., Chu, B. K., Yegya‐Raman, N., Han, X., Doucette, A. G., Poirier, K., Mohiuddin, J. J., Maity, A. M., Facciabene, A., Amaravadi, R. K., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac108 · Cited by 5 · see citing works
Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current Evidence
Foo, T., Rico, G. T., & Roberts‐Thomson, R. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00762-1 · Cited by 3 · see citing works
How to manage side effects of immunotherapy
Kopecký, J., & Kubeček, O. (2020) · Onkologie · doi:10.36290/xon.2020.049 · Cited by 2 · see citing works
Melanoma Diagnosis and Treatment in the Elderly
Babbush, K. M., & Damanpour, S. (2020) · Current Geriatrics Reports · doi:10.1007/s13670-020-00330-w · Cited by 2 · see citing works
Almutairi, A. R., Erstad, B. L., McBride, A., Slack, M. K., & Abraham, I. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1877272 · Cited by 2 · see citing works
“5% incidence of irhypothyroidism in 858 older patients with melanoma treated with ipilimumab [32].”
BackgroundImmune-related adverse events with cancer clinical benefits: a systematic review and meta-analysis
Li, Z., Sun, Q., Yang, X. Y., Ni, J., Zhang, Y., Wang, J., Ding, K., Wang, G., Yang, H., Yu, Q., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16446-9 · Cited by 2 · see citing works
Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma
Foo, T., Rico, G. T., & Brown, M. P. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-235472
- Authors
- Mian, I., Yang, M., Zhao, H., Shah, M., Diab, A., Shannon, V., Patel, A., Amaria, R. N., Giordano, S. H., & Suarez-Almazor, M. E.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-20
- Volume
- 34
- Issue
- 15_suppl
- Pages
- 3047-3047
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2891762335
- Cited by
- 25
- References
- 0
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 4 · 2021: 4 · 2020: 8 · 2019: 4 · 2018: 2 · 2017: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune-related adverse events, ipilimumab, melanoma, elderly patients, overall survival, hypothyroidism, colitis, hypophysitis, skin inflammation, immune checkpoint inhibitors, adverse event severity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
